<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on November 19, 2021</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT04364555</url>
  </required_header>
  <id_info>
    <org_study_id>LIKLO-1</org_study_id>
    <nct_id>NCT04364555</nct_id>
  </id_info>
  <brief_title>Efficacy of Topical Treatment With Clobetasol in Symptomatic Oral Lichen Planus.</brief_title>
  <official_title>Efficacy of Topical Treatment With Clobetasol in Symptomatic Oral Lichen Planus. A Multicenter Placebo-controlled Randomized Clinical Trial.</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Malmö University</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
    <collaborator>
      <agency>Skane University Hospital</agency>
      <agency_class>Other</agency_class>
    </collaborator>
  </sponsors>
  <source>Malmö University</source>
  <oversight_info>
    <has_dmc>Yes</has_dmc>
    <is_fda_regulated_drug>No</is_fda_regulated_drug>
    <is_fda_regulated_device>No</is_fda_regulated_device>
  </oversight_info>
  <brief_summary>
    <textblock>
      The investigators want to study the effect of clobetasol in symptomatic oral lichen planus.&#xD;
      The investigators will include 90 patients and randomly alocate them in three groups. The&#xD;
      frist group will recive active treatment both in the morning an evening. Group two recieves&#xD;
      palcebo in the morning and active treatment in the evening. Group three will get palcebo both&#xD;
      in the morning and in the evening. All Groups will follow the same protocol with rinsing&#xD;
      twice daily with clobetasol in conjunction with antfungal treatment. The patients will be&#xD;
      controlled after two weeks and and again after another two weeks. A biopsy will be performed&#xD;
      at inclusion and another biopsy will be taken at the end of the testperiod. Smears for&#xD;
      candida will also be evaluated. The patients will be examined for change in clinical&#xD;
      apearance and will answer questions to note changes in symptoms. Our hypothesesis: #Patients&#xD;
      recieving clobetasolrinses will have a better resolution af symptoms than those who got&#xD;
      placebo. #Patients treated with clobetasol twice daily will have a faster relief of symptoms&#xD;
      than patients just teated once daily. #The clinical signs of oral lichen planus will diminish&#xD;
      more pronounced in the two groups given active treatment. #A majority of the OLP lesions were&#xD;
      infected by candida. #Specific histological changes can be seen in the biopsies taken after&#xD;
      clobetasoltreatment compared to those taken before treatment.&#xD;
    </textblock>
  </brief_summary>
  <overall_status>Recruiting</overall_status>
  <start_date type="Actual">May 18, 2020</start_date>
  <completion_date type="Anticipated">April 2022</completion_date>
  <primary_completion_date type="Anticipated">April 2022</primary_completion_date>
  <phase>Phase 2/Phase 3</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Parallel Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>Quadruple (Participant, Care Provider, Investigator, Outcomes Assessor)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Clinical apearance of the lichen lesion</measure>
    <time_frame>Four weeks</time_frame>
    <description>Site-, severity- and activity-score acording to Escudier et al</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>Oral health impact profile</measure>
    <time_frame>Four weeks</time_frame>
    <description>Oral health impact profile (OHIP-14)</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Pain score</measure>
    <time_frame>Four weeks</time_frame>
    <description>VAS scale. A 10 cm scale ranging from no pain what so ever to worst pain imagineable.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Burning sensation score</measure>
    <time_frame>Four weeks</time_frame>
    <description>VAS scale. A 10 cm scale ranging from no burning sensation what so ever to worst burning sensation imagineable.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Histological apearance</measure>
    <time_frame>Four weeks</time_frame>
    <description>Amount and degree of lichenoid reaction in biopsy</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Candida</measure>
    <time_frame>baseline (At treatment start)</time_frame>
    <description>Candida hyfes in smear from lichenlesions</description>
  </secondary_outcome>
  <number_of_arms>3</number_of_arms>
  <enrollment type="Anticipated">90</enrollment>
  <condition>Oral Lichen Planus</condition>
  <arm_group>
    <arm_group_label>Active/active</arm_group_label>
    <arm_group_type>Active Comparator</arm_group_type>
    <description>The one bottle for use in the morning has clobetasol-oral gel, and so does the bottle fore use in the evening. The oral cavity will be rinsed with 5ml oral gel during 1 minute. Nystatin will be taken oraly 1ml 4 times daily.</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Placebo/active</arm_group_label>
    <arm_group_type>Active Comparator</arm_group_type>
    <description>The bottle for use in the morning cantains placebo and one for use in the evening contains clobetasol oral gel. The oral cavity will be rinsed with 5ml oral gel during 1 minute. Nystatin will be taken oraly 1ml 4 times daily.</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Placebo/placebo</arm_group_label>
    <arm_group_type>Placebo Comparator</arm_group_type>
    <description>Both bottles, the one for the morning and the one for use in the evening, contains placebo. The oral cavity will be rinsed with 5ml oral gel during 1 minute. Nystatin will be taken oraly 1ml 4 times daily.</description>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Clobetasol Propionate</intervention_name>
    <description>Klobetasol APL oral gel 0.025% is a topical steroid for rinsing the oral cavity. Manufactured by APL, Sweden.</description>
    <arm_group_label>Active/active</arm_group_label>
    <other_name>Klobetasol APL oral gel 0.025%</other_name>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Placebo/active</intervention_name>
    <description>Placebo/active</description>
    <arm_group_label>Placebo/active</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Placebo/placebo</intervention_name>
    <description>Placebo/placebo</description>
    <arm_group_label>Placebo/placebo</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:&#xD;
&#xD;
          -  Symptomatic oral lichen planus&#xD;
&#xD;
          -  Age above 40 years&#xD;
&#xD;
        Exclusion Criteria:&#xD;
&#xD;
          -  Lichenoid contactlesions&#xD;
&#xD;
          -  Graft versus host disease&#xD;
&#xD;
          -  Bacteriarelated lichenoid reaction&#xD;
&#xD;
          -  Intraoral vesiculobulous diseases&#xD;
&#xD;
          -  Active antbiotic treatment&#xD;
&#xD;
          -  Active treatment with steroids or other immunomodelling substance&#xD;
&#xD;
          -  Alergy to Clobetasol&#xD;
&#xD;
          -  Severe periodontitis&#xD;
&#xD;
          -  Bad oral hygiene&#xD;
&#xD;
          -  Biopsy not supporting OLP&#xD;
&#xD;
          -  Alergy to nystatin&#xD;
&#xD;
          -  Not in menopaus&#xD;
&#xD;
          -  Previous or actual oral malignancy&#xD;
&#xD;
          -  Participation in other medical study&#xD;
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>40 Years</minimum_age>
    <maximum_age>N/A</maximum_age>
    <healthy_volunteers>Accepts Healthy Volunteers</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Bengt Götrick, Docent</last_name>
    <role>Study Chair</role>
    <affiliation>Malmö University</affiliation>
  </overall_official>
  <overall_contact>
    <last_name>Fredrik Gränse, DDS</last_name>
    <phone>0046736954499</phone>
    <email>fredrik.granse@mau.se</email>
  </overall_contact>
  <overall_contact_backup>
    <last_name>Bengt Götrick, Docent</last_name>
    <phone>0046406658427</phone>
    <email>bengt.gotrick@mau.se</email>
  </overall_contact_backup>
  <location>
    <facility>
      <name>Oral surgery, Universityhospital of Scania</name>
      <address>
        <city>Lund</city>
        <zip>22242</zip>
        <country>Sweden</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Fredrik Gränse, Doctoral student</last_name>
      <phone>0046406658432</phone>
      <email>fredrik.granse@mau.se</email>
    </contact>
    <contact_backup>
      <last_name>Cecilia Wexell, Docent</last_name>
      <phone>004646174320</phone>
      <email>cecilia.wexell@skane.se</email>
    </contact_backup>
  </location>
  <location>
    <facility>
      <name>Oral Surgery and oral medicine, Malmö University</name>
      <address>
        <city>Malmö</city>
        <zip>20506</zip>
        <country>Sweden</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Fredrik Gränse, Doctoral student</last_name>
      <phone>0046406658432</phone>
      <email>fredrik.granse@mau.se</email>
    </contact>
    <contact_backup>
      <last_name>Bengt Götrick, Docent</last_name>
      <phone>0046406658427</phone>
      <email>bengt.gotrick@mau.se</email>
    </contact_backup>
  </location>
  <location_countries>
    <country>Sweden</country>
  </location_countries>
  <verification_date>September 2020</verification_date>
  <study_first_submitted>April 24, 2020</study_first_submitted>
  <study_first_submitted_qc>April 27, 2020</study_first_submitted_qc>
  <study_first_posted type="Actual">April 28, 2020</study_first_posted>
  <last_update_submitted>September 8, 2020</last_update_submitted>
  <last_update_submitted_qc>September 8, 2020</last_update_submitted_qc>
  <last_update_posted type="Actual">September 10, 2020</last_update_posted>
  <responsible_party>
    <responsible_party_type>Principal Investigator</responsible_party_type>
    <investigator_affiliation>Malmö University</investigator_affiliation>
    <investigator_full_name>Fredrik Gränse</investigator_full_name>
    <investigator_title>Dentist</investigator_title>
  </responsible_party>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Lichen Planus, Oral</mesh_term>
    <mesh_term>Lichen Planus</mesh_term>
  </condition_browse>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Clobetasol</mesh_term>
  </intervention_browse>
  <patient_data>
    <sharing_ipd>No</sharing_ipd>
    <ipd_description>Still undecided since we dont know what data to share and how, yet.</ipd_description>
  </patient_data>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

